Muc16 chimeric antigen receptors
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsTina Albershardt, Geoffrey Blackburn Parsons, David Dilillo
Life of this patent
Estimating the term…
Abstract
The present disclosure provides chimeric antigen receptors (CARs) targeting MUC16, genetically modified immune effector cells, and use of these compositions to treat cancer.
Claims102
A chimeric antigen receptor (CAR) comprising:
- an extracellular domain comprising an anti-MUC16 antibody or antigen binding fragment thereof that binds one or more epitopes of a human MUC16 polypeptide;
- a transmembrane domain, one or more intracellular co-stimulatory signaling domains, and a primary signaling domain.
A polynucleotide encoding a CAR, wherein the polynucleotide sequence encodes a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to, or comprises SEQ ID NO:
- 10 or SEQ ID NO:
- 12.
A polynucleotide encoding a CAR, wherein the polynucleotide sequence encodes a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to, or comprising any one of SEQ ID NOs:
- 9, 11, 49, 50, 51, 52, 61, 62, 63, 64, 73, 74, 75, 76, 85, 86, 87, 88, 97, 98, 99, 100, 109, 110, 111, 112, 121, 122, 123, 124, 125, 126, 135, 136, 137, 138, 147, 148, 149 or 150.
Dependencies are inferred from the claim text.